Kapustová Adriana, Macášek Patrik, Baďurová Bibiána, Melegová Jana, Rimpelová Silvie, Kubovčiak Jan, Šáchová Jana, Hradilová Miluše, Kolář Michal, Vítek Libor, Ruml Tomáš, Gbelcová Helena
Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia.
Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University, Malá Hora 4, 036 01 Marti, Slovakia.
Biomedicines. 2025 Jul 14;13(7):1714. doi: 10.3390/biomedicines13071714.
The progressive course of coronavirus disease 2019 (COVID-19) is more frequently observed in individuals with obesity, diabetes, pulmonary and cardiovascular disease, or arterial hypertension. Many patients with these conditions are prescribed statins to treat hypercholesterolaemia. However, statins exhibit additional pleiotropic effects. The present study aims to investigate the effects of all eight currently existing statins on the expression of genes whose products have been reported to be directly associated with complicated COVID-19 disease. We extended the interpretation of the whole-genome DNA microarray analyses of pancreatic cancer cells MiaPaCa-2 and whole-transcriptome analyses of adipose tissue-derived mesenchymal stem cells AD-MSC that we had performed in the past. From the number of genes with altered expression induced by statins, we focused on those reported to be involved in a complicated course of COVID-19, including and , genes encoding proteins involved in innate antiviral immunity and respiratory failure genes. Although we did not observe statin-induced changes in the expression of , and any of the six genes clustered in the locus associated with respiratory failure in patients with COVID-19, some statins induced changes in the expression of genes encoding their interaction partners. Among genes associated with the immune system, all statins, which are effective in vitro affected the expression of genes encoding IL-6 and IL-8 and interaction partners of NF-kB, which may influence the duration of viral persistence. Statins act on multiple pathways simultaneously, some of which support COVID-19 development, while others suppress it.
2019冠状病毒病（COVID-19）的进展过程在肥胖、糖尿病、肺部和心血管疾病或动脉高血压患者中更为常见。许多患有这些疾病的患者会服用他汀类药物来治疗高胆固醇血症。然而，他汀类药物还具有其他多效性作用。本研究旨在调查目前现有的所有八种他汀类药物对其产物据报道与复杂COVID-19疾病直接相关的基因表达的影响。我们扩展了对过去所进行的胰腺癌细胞MiaPaCa-2的全基因组DNA微阵列分析以及脂肪组织来源的间充质干细胞AD-MSC的全转录组分析的解读。从他汀类药物诱导表达改变的基因数量中，我们重点关注那些据报道与COVID-19复杂病程相关的基因，包括 以及 ，即编码参与先天性抗病毒免疫的蛋白质的基因和呼吸衰竭相关基因。尽管我们未观察到他汀类药物诱导COVID-19患者中 、 以及与呼吸衰竭相关位点聚集的六个基因中的任何一个基因的表达发生变化，但一些他汀类药物诱导了编码其相互作用伙伴的基因表达发生变化。在与免疫系统相关的基因中，所有在体外有效的他汀类药物都会影响编码IL-6和IL-8以及NF-κB相互作用伙伴的基因表达，这可能会影响病毒持续存在的时间。他汀类药物同时作用于多个途径，其中一些途径支持COVID-19的发展，而另一些则抑制它。
